JAK Inhibitors

Herpes zoster infections after vaccination with a recombinant, adjuvanted vaccine (Shingrix) against herpes zoster in rheumatoid arthritis patients receiving JAK-inhibitors

Background: Patients with rheumatoid arthritis (RA) treated with Janus kinase inhibitors (JAKi) have an increased risk of herpes zoster (HZ). A non‑live, recombinant subunit vaccine (Shingrix) offers protection in adults aged ≥50 years, but its …